Literature DB >> 16914758

Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis.

S Vulliemoz1, F Lurati-Ruiz, F-X Borruat, J Delavelle, I J Koralnik, T Kuntzer, J Bogousslavsky, F Picard, T Landis, R A Du Pasquier.   

Abstract

Progressive multifocal leucoencephalopathy (PML), a demyelinating disease caused by the JC virus (JCV), occurs in immunosuppressed patients and carries a poor prognosis. A favourable outcome is reported in two patients with PML and dermatomyositis. Immunosuppressive drugs were stopped in patient 1 but could only be partially tapered in patient 2. The JCV-specific CD8+ T cell response was strong in patient 1 and weak in patient 2. Both were treated with cytosine-arabinoside, and patient 2 was also treated with mirtazapine, a 5HT2A receptor antagonist. Combination of these drugs might be helpful to treat HIV-negative patients with PML.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914758      PMCID: PMC2077730          DOI: 10.1136/jnnp.2006.092353

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  Unsuccessful treatment with cidofovir and cytarabine in progressive multifocal leukoencephalopathy associated with dermatomyositis.

Authors:  N Tubridy; C Wells; D Lewis; F Schon
Journal:  J R Soc Med       Date:  2000-07       Impact factor: 5.344

2.  Progressive multifocal leucoencephalopathy and immunosuppression.

Authors:  L A Cuevas; H A Fuchs
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

Review 3.  Progressive multifocal leukoencephalopathy during cyclosporine treatment. A case report.

Authors:  S Gentile; I Sacerdote; D Roccatello; M T Giordana
Journal:  Ital J Neurol Sci       Date:  1996-10

4.  The distribution of neuroglia and schwann cells in the 8th nerve of man.

Authors:  M W Bridger; J Farkashidy
Journal:  J Laryngol Otol       Date:  1980-12       Impact factor: 1.469

5.  Early events in the life cycle of JC virus as potential therapeutic targets for the treatment of progressive multifocal leukoencephalopathy.

Authors:  S Baum; A Ashok; G Gee; S Dimitrova; W Querbes; J Jordan; Walter J Atwood
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

6.  Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside.

Authors:  A J Aksamit
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

7.  The human polyomavirus, JCV, uses serotonin receptors to infect cells.

Authors:  Gwendolyn F Elphick; William Querbes; Joslynn A Jordan; Gretchen V Gee; Sylvia Eash; Kate Manley; Aisling Dugan; Megan Stanifer; Anushree Bhatnagar; Wesley K Kroeze; Bryan L Roth; Walter J Atwood
Journal:  Science       Date:  2004-11-19       Impact factor: 47.728

8.  Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.

Authors:  Manfred Uhr; Markus T Grauer; Florian Holsboer
Journal:  Biol Psychiatry       Date:  2003-10-15       Impact factor: 13.382

9.  Classification criteria for polymyositis and dermatomyositis.

Authors:  K Tanimoto; K Nakano; S Kano; S Mori; H Ueki; H Nishitani; T Sato; T Kiuchi; Y Ohashi
Journal:  J Rheumatol       Date:  1995-04       Impact factor: 4.666

10.  Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy.

Authors:  Renaud A Du Pasquier; Marcelo J Kuroda; Joern E Schmitz; Yue Zheng; Kristi Martin; Fred W Peyerl; Michelle Lifton; Darci Gorgone; Patrick Autissier; Norman L Letvin; Igor J Koralnik
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more
  23 in total

Review 1.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

Review 2.  Progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2007-11       Impact factor: 5.081

Review 3.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

4.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 5.  Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.

Authors:  Eric M L Williamson; Joseph R Berger
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

6.  Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine.

Authors:  Rebekka Kurmann; Christian Weisstanner; Piotr Kardas; Hans H Hirsch; Roland Wiest; Bernhard Lämmle; Hansjakob Furrer; Renaud Du Pasquier; Claudio L Bassetti; Mathias Sturzenegger; Heinz Krestel
Journal:  J Neurovirol       Date:  2015-04-28       Impact factor: 2.643

Review 7.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

8.  Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells.

Authors:  Moti L Chapagain; Laarni Sumibcay; Ulziijargal Gurjav; Pakieli H Kaufusi; Richard E Kast; Vivek R Nerurkar
Journal:  J Neurovirol       Date:  2008-11-12       Impact factor: 2.643

9.  Long-Term Survival after Progressive Multifocal Leukoencephalopathy in a Patient with Primary Immune Deficiency and NFKB1 Mutation.

Authors:  Emke Maréchal; Karolien Beel; Roel Crols; Danielle Hernalsteen; Barbara Willekens
Journal:  J Clin Immunol       Date:  2020-09-11       Impact factor: 8.317

10.  Progressive multifocal leukoencephalopathy.

Authors:  Allen J Aksamit
Journal:  Curr Treat Options Neurol       Date:  2008-05       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.